Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALGS NASDAQ:DTIL NASDAQ:DYAI NASDAQ:ESLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$4.91-8.1%$6.53$4.80▼$13.69$30.38M2.25138,153 shs127,991 shsDTILPrecision BioSciences$6.50+1.4%$6.98$3.53▼$8.82$167.71M1.3303,134 shs253,228 shsDYAIDyadic International$0.71-1.8%$0.79$0.65▼$1.35$25.89M1.17593,755 shs79,647 shsESLAEstrella Immunopharma$1.14-0.9%$1.36$0.78▼$3.15$49.06M0.8534,974 shs6,645 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics-8.05%-13.86%-22.92%-29.66%-21.94%DTILPrecision BioSciences+1.40%-6.74%-13.56%+41.00%+27.45%DYAIDyadic International-1.77%-12.05%-6.51%-7.43%-26.74%ESLAEstrella Immunopharma0.00%+4.59%-12.31%+6.54%+15.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALGSAligos Therapeutics$4.91-8.1%$6.53$4.80▼$13.69$30.38M2.25138,153 shs127,991 shsDTILPrecision BioSciences$6.50+1.4%$6.98$3.53▼$8.82$167.71M1.3303,134 shs253,228 shsDYAIDyadic International$0.71-1.8%$0.79$0.65▼$1.35$25.89M1.17593,755 shs79,647 shsESLAEstrella Immunopharma$1.14-0.9%$1.36$0.78▼$3.15$49.06M0.8534,974 shs6,645 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALGSAligos Therapeutics-8.05%-13.86%-22.92%-29.66%-21.94%DTILPrecision BioSciences+1.40%-6.74%-13.56%+41.00%+27.45%DYAIDyadic International-1.77%-12.05%-6.51%-7.43%-26.74%ESLAEstrella Immunopharma0.00%+4.59%-12.31%+6.54%+15.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALGSAligos Therapeutics 2.86Moderate Buy$38.50684.11% UpsideDTILPrecision BioSciences 2.50Moderate Buy$36.33458.97% UpsideDYAIDyadic International 2.33Hold$3.00322.18% UpsideESLAEstrella Immunopharma 2.00Hold$8.00601.75% UpsideCurrent Analyst Ratings BreakdownLatest DTIL, ALGS, ESLA, and DYAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight5/28/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/28/2026ALGSAligos Therapeutics Lake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$45.005/27/2026DTILPrecision BioSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/21/2026ALGSAligos Therapeutics Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/14/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026DTILPrecision BioSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/29/2026ESLAEstrella Immunopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)4/20/2026ALGSAligos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026DTILPrecision BioSciences JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$30.00(Data available from 6/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALGSAligos Therapeutics$2.19M13.88N/AN/A$8.67 per share0.57DTILPrecision BioSciences$34.26M4.89N/AN/A$4.03 per share1.61DYAIDyadic International$3.09M8.38N/AN/A$0.03 per share23.69ESLAEstrella ImmunopharmaN/AN/AN/AN/A($0.27) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALGSAligos Therapeutics-$24.19M-$8.69N/AN/AN/A-1,919.68%-139.47%-90.88%8/5/2026 (Estimated)DTILPrecision BioSciences-$45.72M-$3.67N/AN/AN/A-96.73%-85.37%-37.34%8/6/2026 (Estimated)DYAIDyadic International-$7.36M-$0.23N/AN/AN/A-192.40%-1,005.45%-77.64%8/12/2026 (Estimated)ESLAEstrella Immunopharma-$13.06M-$0.34N/AN/AN/AN/AN/A-397.36%N/ALatest DTIL, ALGS, ESLA, and DYAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026ESLAEstrella Immunopharma-$0.0840-$0.05+$0.0340-$0.05N/AN/A5/13/2026Q1 2026DYAIDyadic International-$0.04-$0.05-$0.01-$0.05$0.90 million$1.11 million5/7/2026Q1 2026ALGSAligos Therapeutics-$2.29-$2.21+$0.08-$2.21$0.25 million$2.83 million5/5/2026Q1 2026DTILPrecision BioSciences-$0.6550-$0.75-$0.0950-$0.75$4.05 million$10.84 million3/25/2026Q4 2025DYAIDyadic International-$0.03-$0.06-$0.03-$0.06$1.34 million$0.57 million3/18/2026Q4 2025ESLAEstrella Immunopharma-$0.18-$0.01+$0.17-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthALGSAligos TherapeuticsN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/ADYAIDyadic InternationalN/AN/AN/AN/AN/AESLAEstrella ImmunopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALGSAligos TherapeuticsN/A2.562.56DTILPrecision BioSciences0.2914.0214.02DYAIDyadic International4.082.422.42ESLAEstrella ImmunopharmaN/A0.240.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALGSAligos Therapeutics60.43%DTILPrecision BioSciences37.99%DYAIDyadic International27.95%ESLAEstrella Immunopharma0.35%Insider OwnershipCompanyInsider OwnershipALGSAligos Therapeutics7.80%DTILPrecision BioSciences2.70%DYAIDyadic International20.90%ESLAEstrella Immunopharma5.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALGSAligos Therapeutics906.19 million5.71 millionNo DataDTILPrecision BioSciences20025.80 million25.11 millionNo DataDYAIDyadic International736.44 million28.82 millionOptionableESLAEstrella ImmunopharmaN/A43.03 million40.54 millionNot OptionableDTIL, ALGS, ESLA, and DYAI HeadlinesRecent News About These CompaniesEstrella Immunopharma, Inc. (NASDAQ:ESLA) Sees Significant Drop in Short InterestJune 3 at 3:21 AM | americanbankingnews.comEstrella Immunopharma to Participate in the D. Boral Capital Global ConferenceMay 5, 2026 | businesswire.comWhy Estrella Immunopharma, Inc.’s (ESLA) Stock Is Up 11.00%April 9, 2026 | aaii.comAEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap ResearchMarch 23, 2026 | finance.yahoo.comESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHLFebruary 10, 2026 | msn.comEstrella Immunopharma (ESLA) price target decreased by 50.00% to 8.16February 4, 2026 | msn.comEstrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®February 3, 2026 | finance.yahoo.comEstrella Immunopharma Receives Nasdaq Non-Compliance NoticeJanuary 15, 2026 | theglobeandmail.comEstrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private PlacementJanuary 6, 2026 | businesswire.comEstrella Immunopharma stock falls after announcing $8 million offeringJanuary 5, 2026 | in.investing.comEstrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq RulesJanuary 5, 2026 | finance.yahoo.comEstrella Immunopharma files to sell 2.54M shares of common stock for holdersDecember 22, 2025 | msn.comWhy Estrella Immunopharma, Inc.’s (ESLA) Stock Is Up 7.90%December 17, 2025 | aaii.comAEstrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB RecommendationDecember 4, 2025 | caledonianrecord.comCEstrella Immunopharma shares gain as CD19 cancer therapy progresses into phase IIDecember 4, 2025 | msn.comEstrella Immunopharma stock rises as cancer therapy advances to Phase IIDecember 4, 2025 | investing.comWhy Estrella Immunopharma, Inc.’s (ESLA) Stock Is Down 7.11%December 1, 2025 | aaii.comAEstrella Immunopharma Achieves Milestone in STARLIGHT-1 TrialNovember 7, 2025 | msn.comEstrella Immunopharma stock soars after 100% complete response rate in trialNovember 4, 2025 | in.investing.comEstrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable PatientsNovember 4, 2025 | joplinglobe.comJNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 2026How Bad Could Tesla’s Cybertruck Recall Be for Shares?By Sam Quirke | May 13, 2026Tesla Ends Model S and X Era, Bets Everything on What's NextBy Sam Quirke | May 20, 2026Wall Street Is Starting to Talk About Tesla's EndgameBy Sam Quirke | May 29, 2026Tesla’s EV Rebound Leaves Rivian and Lucid Facing a Tougher Investor TestBy Jessica Mitacek | June 6, 2026DTIL, ALGS, ESLA, and DYAI Company DescriptionsAligos Therapeutics NASDAQ:ALGS$4.91 -0.43 (-8.05%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$5.07 +0.16 (+3.34%) As of 06/5/2026 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Precision BioSciences NASDAQ:DTIL$6.50 +0.09 (+1.40%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$6.42 -0.08 (-1.23%) As of 06/5/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Dyadic International NASDAQ:DYAI$0.71 -0.01 (-1.77%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.70 -0.01 (-1.35%) As of 06/5/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein produced using the C1 platform. It has also developed the Dapibus thermophilic, a filamentous fungal-based microbial protein production platform to enable the development and large-scale manufacture of cost-effective proteins, metabolites, and other biologic products for use in non-pharmaceutical applications, including food, nutrition, and wellness. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; license agreement with South Africa's Rubic One Health; Joint Development Agreement with a Global Food Ingredient Company; and sub-license agreement with Abic Biological Laboratories Ltd., Alphazyme, LLC, and Abic Biological Laboratories Ltd. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.Estrella Immunopharma NASDAQ:ESLA$1.14 -0.01 (-0.87%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$1.14 0.00 (0.00%) As of 06/5/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/01 - 06/05 Samsara Just Answered The AI Question—Is Wall Street Ready To Listen? A Lulu of a Miss Sends Lululemon to New Lows—Look Out Below Five Below Down 12% Post Earnings—Is the Selloff Overdone? IREN's 800MW Bet Flips the AI Power Switch Buy the Dip? Broadcom's AI Moat Is Wider Than Ever CrowdStrike Earnings Beat Sparks Selloff—Buy the Dip? The Market Has Ollie’s Bargain Outlet Completely Wrong Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
